
Cellestia ’s CB-103 in achieving complete response
22.06.2022
A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient...
22.06.2022
A case study shows contribution of Cellestia ’s CB-103 in achieving complete response in a relapse/refractor T-ALL patient...
21.06.2022
BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098...
08.06.2022
BioVersys AG announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR...
29.04.2022
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to ...
18.03.2022
Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the entry into a definitive agreement to acquire...